MINNEAPOLIS, MN — The SYMPLICITY HTN-3 trial, a phase 3 study testing catheter-based renal denervation for the treatment of resistant hypertension, failed to achieve its primary efficacy end point, ...
Medtronic plc (NYSE:MDT) announced Thursday that Japan’s Ministry of Health, Labour and Welfare has granted reimbursement ...
SAN DIEGO, CA—Renal denervation using ultrasound may be more effective than radiofrequency ablation for lowering blood pressure in patients with resistant hypertension, a preliminary head-to-head ...
RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...
SAN DIEGO, CA—Concordant with studies of other technologies for renal denervation, the presence of untreated accessory arteries was associated with a reduced blood pressure-lowering response to the ...
DUBLIN and CHICAGO, Nov. 7, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the six-month results from the full cohort of the SPYRAL HTN-ON MED ...
Mineralys Therapeutics announced the positive results of its Launch-HTN trial, the largest study of an aldosterone synthase inhibitor for patients with uncontrolled or treatment-resistant hypertension ...
It's almost impossible to keep up with what things mean on TikTok, which is mostly thanks to the users who come up with phrases, memes, and acronyms almost daily. And when one sticks, you'd better be ...
Role of single nucleotide polymorphisms of gemcitabine metabolic genes in metastatic colorectal cancer patients treated with gemcitabine-based salvage therapy. Background: There are no known ...
MINNEAPOLIS, MN — Catheter-based renal denervation for the treatment of resistant hypertension has featured prominently at recent hypertension and cardiology congresses in the past few years, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results